Regional Health is involved in prostate cancer research trials. Below is more information about the purpose and who the physician (principal investigator) is for each trial. For more in-depth information on the research studies, click the blue name which will lead you to the U.S. National Institute of Health website or call (605) 755-2300.
Phase III Trial of Enzalutamide (NSC #766085) vs Enzalutamide, Abiraterone and Prednisone for Castration Resistent Metastatic Prostate Cancer
PURPOSE: This randomized phase III trial studies enzalutamide to see how well it works compared to enzalutamide, abiraterone acetate, and prednisone in treating patients with castration-resistant metastatic prostate cancer. Androgens can cause the growth of prostate cancer cells. Drugs, such as enzalutamide, abiraterone acetate, and prednisone, may lessen the amount of androgens made by the body.
|To learn more, contact:
John T. Vucurevich Cancer Care Institute
Joshua Lukenbill, DO